We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+15.65%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$515M
AUM Growth
+$28.6M
Cap. Flow
+$7.92M
Cap. Flow %
1.54%
Top 10 Hldgs %
33.78%
Holding
87
New
22
Increased
22
Reduced
21
Closed
22

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$18.1M
2
BSX icon
Boston Scientific
BSX
+$14M
3
CAH icon
Cardinal Health
CAH
+$12.7M
4
BIIB icon
Biogen
BIIB
+$10.6M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$10.1M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$15.5M
2
LLY icon
Eli Lilly
LLY
+$15.2M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$14.2M
4
ELV icon
Elevance Health
ELV
+$13.3M
5
DXCM icon
DexCom
DXCM
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$7.83M 1.52%
230,000
-58,058
-20% -$888K
DHR icon
27
Danaher
DHR
$146B
$7.75M 1.51%
+33,840
New +$8.28M
UNH icon
28
UnitedHealth
UNH
$365B
$7.58M 1.47%
+15,000
New +$7.89M
INSP icon
29
Inspire Medical Systems
INSP
$1.71B
$7.09M 1.38%
+40,000
New +$8.04M
NTLA icon
30
Intellia Therapeutics
NTLA
$1.68B
$7M 1.36%
125,000
+41,505
+50% +$2.57M
KURA icon
31
Kura Oncology
KURA
$882M
$6.83M 1.33%
500,000
+38,690
+8% +$597K
ISEE
32
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.73M 1.31%
+375,000
New +$4.92M
THC icon
33
Tenet Healthcare
THC
$20.9B
$6.71M 1.3%
130,000
-120,485
-48% -$7.15M
KRYS icon
34
Krystal Biotech
KRYS
$9.68B
$6.27M 1.22%
90,000
+37,816
+72% +$2.73M
IRTC icon
35
iRhythm Holdings
IRTC
$4.02B
$6.26M 1.22%
50,000
-7,403
-13% -$1.07M
DVA icon
36
DaVita
DVA
$11.4B
$6.21M 1.21%
75,000
+22,816
+44% +$2M
BPMC
37
DELISTED
Blueprint Medicines
BPMC
$6.13M 1.19%
93,000
-37,000
-28% -$2.38M
PODD icon
38
Insulet
PODD
$10B
$5.74M 1.11%
+25,000
New +$6.26M
ILMN icon
39
Illumina
ILMN
$29.1B
$5.72M 1.11%
+30,840
New +$6.1M
ACRS icon
40
Aclaris Therapeutics
ACRS
$871M
$5.35M 1.04%
340,000
+54,029
+19% +$851K
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.89M 0.95%
+70,000
New +$5.18M
EXAS
42
DELISTED
Exact Sciences
EXAS
$4.87M 0.95%
+150,000
New +$6.18M
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$4.78M 0.93%
70,000
-29,150
-29% -$1.72M
NVRO
44
DELISTED
NEVRO CORP.
NVRO
$4.66M 0.91%
100,000
+21,723
+28% +$1.01M
ALKS icon
45
Alkermes
ALKS
$8.26B
$4.47M 0.87%
200,000
-61,966
-24% -$1.61M
RVNC
46
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.05M 0.79%
+150,000
New +$3.04M
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
$3.71M 0.72%
195,000
+38,447
+25% +$886K
GOSS icon
48
Gossamer Bio
GOSS
$88.9M
$3.59M 0.7%
+300,000
New +$3.72M
DNLI icon
49
Denali Therapeutics
DNLI
$3.95B
$3.53M 0.69%
+115,000
New +$3.74M
SIBN icon
50
SI-BONE Inc
SIBN
$843M
$3.49M 0.68%
200,000
+42,683
+27% +$682K
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Integral Health Asset Management held 87 positions worth $515M, up 5.9% from $486M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Integral Health Asset Management's Q3 2022 filing shows 22 new, 22 increased, 21 reduced and 22 closed positions. Its largest new stake was Baxter International: 300,000 shares worth $16.2M. The largest sale was AstraZeneca, an estimated $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

  • Integral Health Asset Management's largest Q3 2022 buy was Baxter International: 300,000 shares worth $16.2M.
  • Integral Health Asset Management added most to CRISPR Therapeutics in Q3 2022, an estimated $10.1M increase.
  • Integral Health Asset Management's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $15.2M.
  • Integral Health Asset Management fully exited AstraZeneca in Q3 2022, selling an estimated $15.5M.
  • Integral Health Asset Management's ten largest holdings make up 34% of its $515M portfolio in Q3 2022.
  • Integral Health Asset Management opened 22 new positions and closed 22 in Q3 2022.
  • Integral Health Asset Management's portfolio value rose 5.9% quarter-over-quarter to $515M.

Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.